We highlight six tocilizumab responsive genes (ARID5A, BCL3, PIM1, SOCS3, BATF, MYC) that are associated with IL-6 pathway and known to be perturbed by tocilizumab treatment in rheumatoid arthritis patients49. This evidence concerns the gene PIM1 and rheumatoid arthritis.